Morusin shows suppression of NFκB and STAT3 in many cancer cell lines including HT-29, A549, MCF-7, and MDA-MB-231. It is a flavonoid purified from the root bark of morus alba L. with antitumor activity.
Morusin is a prenylated flavonoid isolated from M. australis with various biological activities, such as antitumor, antioxidant, and anti-bacteria property. Morusin shows suppression of NF-κB and STAT3 in many cancer cell lines including HT-29, A549, MCF-7, and MDA-MB-231. Morusin exhibits a dose- and time-dependent inhibitory effect on murine and human breast cancer cells. IC50 is 9.48 μg/mL for normal mammary epithelial cells (MCF-10A); 2.03 and 1.87 μg/mL for murine breast cancer cells (4 T1 and EMT6); and 2.71 and 3.86 μg/mL for human breast cancer cells (MCF-7 and MDA-MB-231), respectively, the maximal inhibition of cell growth (>80 %) is obtained at 8 μg/mL[3]. Morusin significantly inhibited the growth and clonogenicity of human colorectal cancer HT-29 cells. Morusin also inhibited the phosphorylation of IKK-alpha, IKK-beta and IkappaB-alpha, increased expression of IkappaB-alpha, and suppressed nuclear translocation of NF-kappaB and its DNA binding activity[4]. Morusin reduces the OA (Osteoarthritis) inflammatory response in vitro and protects against articular cartilage degradation in vivo potentially via regulation of the NF-κB pathway[5]. Morusin could inhibit the growth of RCC (Renal cell carcinoma) cells in vitro and in vivo through MAPK signal pathways[6].
搜索
